Molecular Formula | C6H13NO3 |
Molar Mass | 147.17 |
Density | 1.279±0.06 g/cm3(Predicted) |
Boling Point | 317.2±37.0 °C(Predicted) |
Solubility | Soluble in water and ethanol. |
Appearance | Yellow low melting point solid |
pKa | 14.19±0.60(Predicted) |
Storage Condition | 2-8°C(protect from light) |
MDL | MFCD04039581 |
In vivo study | Afegostat (AT2101) increases GCase activity in brain, liver, and spleen. Afegostat (100 mg/kg) administrates orally for 4 months to Thy1-aSyn mice improved motor and nonmotor function, abolishes microglial inflammatory response in the substantia nigra, reduces α-synuclein immunoreactivity in nigral dopaminergic neurons, and reduces the number of small α-synuclein aggregates, while increasing the number of large α-synuclein aggregates. |
Biological activity | Afegostat is a pharmacological partner, high affinity and specific and reversible binding Acid β-glucosidase (GCase) in the endoplasmic reticulum (ER). |
target | GCase |
in vivo research | Afegostat (AT2101) increases GCase activity in brain, liver, and spleen. Afegostat (100 mg/kg) administrates orally for 4 months to Thy1-aSyn mice improved motor and nonmotor function, abolishes microglial inflammatory response in the substantia nigra, reduces α-synuclein immunoreactivity in nigral dopaminergic neurons, and reduces the number of small α-synuclein aggregates, while increasing the number of large α-synuclein aggregates. |